Feasibility study confirms highly effective therapy concept from tech2people.
Paraplegia, multiple sclerosis, stroke – all these diagnoses have one thing in common: movement restrictions or paralysis. With the help of the latest technologies and artificial intelligence (AI), MedTech start-up tech2people from Vienna has succeeded in helping people with a wide variety of movement restrictions “back on their feet”.
Revolutionary therapy approach: From the wheelchair into the exoskeleton.
Therapy analysis used in the past has relied primarily on patient interviews and relatively simple metrics. The use of robotics will develop this further in the long term. With the help of an exoskeleton, the therapy of people with neurological diseases such as paraplegia, multiple sclerosis or stroke can be drastically improved. The exoskeleton, a robotic suit, enables people with paralysis to walk again under the guidance of a physical therapist. This reactivates the musculoskeletal system and increases the mobility of the entire organism.
Feasibility study confirms unique therapeutic success
The tech2people company, which founded the first outpatient therapy program with exoskeleton in Vienna in 2018, is now setting new standards in the research of robotic therapy. In a cooperation with Research Studios Austria FG (RSA FG), a research company focusing on digital intelligence and future technologies, a decisive advance was made in the analysis of complex and extensive sensor data of different devices in the therapy environment. The result of the feasibility study impressively demonstrates that not only is a data-based evaluation of this therapy feasible, but that this information can be used to measurably improve therapy outcomes.
“This is a remarkable result,” says Benedikt Gollan, scientific studio manager of the Research Studio Pervasive Computing Applications at RSA FG. “By using digital technologies, therapy progress can be measured in detail. For the first time, high-quality, high-resolution data is available that allows much more accurate, holistic therapy analyses and describes the quality of movement.”
Michael Seitlinger, co-founder of tech2people, is also enthusiastic: “With the result of the feasibility study, we were able to show that our approach of a manufacturer-independent multi-sensor fusion of robotics-assisted therapy is very promising and, above all, implementable. With this data and the support of artificial intelligence, we will sustainably increase the efficiency of therapy. This is very good news for all people suffering from neurologically related movement limitations.”
Author: Benedikt Gollan
First publication: OTS
